Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed Orally

Stock Information for Avenue Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Avenue Therapeutics Inc.

Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003
Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop
Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit
Enveric Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Aries Science & Technology and Enveric Biosciences Announce Issuance of Key US Patent Under Aries' License for Treatment of Radiation Dermatitis and Other Conditions
Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results
Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement
Enveric Biosciences Announces Patent Granted for Drug Candidate

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.